» Articles » PMID: 35841311

Prevalence and Treatments of Movement Disorders in Prion Diseases: A Longitudinal Cohort Study

Overview
Journal Mov Disord
Date 2022 Jul 16
PMID 35841311
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prion diseases cause a range of movement disorders involving the cortical, extrapyramidal, and cerebellar systems, and yet there are no large systematic studies of their prevalence, features, associations, and responses to commonly used treatments.

Objectives: We sought to describe the natural history and pharmacological management of movement disorders in prion diseases.

Methods: We studied the serial examination findings, investigation results, and symptomatic treatment recorded for 700 patients with prion diseases and 51 mimics who had been enrolled onto the prospective longitudinal National Prion Monitoring Cohort study between 2008 and 2020. We performed an analysis to identify whether there were patterns of movement disorders associated with disease aetiology, PRNP codon 129 polymorphism, disease severity rating scales, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) findings.

Results: Gait disturbances, myoclonus, and increased tone are the most frequently observed movement disorders in patients with prion diseases. The typical pattern of early motor dysfunction involves gait disturbance, limb ataxia, impaired smooth pursuit, myoclonus, tremor, and increased limb tone. Disturbances of gait, increased tone, and myoclonus become more prevalent and severe as the disease progresses. Chorea, alien limb phenomenon, and nystagmus were the least frequently observed movement disorders, with these symptoms showing spontaneous resolution in approximately half of symptomatic patients. Disease severity and PRNP codon 129 polymorphism were associated with different movement disorder phenotypes. Antiepileptics and benzodiazepines were found to be effective in treating myoclonus.

Conclusions: We describe the prevalence, severity, evolution, treatment, and associated features of movement disorders in prion diseases based on a prospective cohort study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Citing Articles

Creutzfeldt-Jakob Disease and Fatal Familial Insomnia: Demographics and In-Hospital Mortality in Spain.

Cuadrado-Corrales N, Lopez-de-Andres A, Hernandez-Barrera V, de-Miguel-Diez J, Jimenez-Sierra A, Carabantes-Alarcon D J Clin Med. 2024; 13(15).

PMID: 39124670 PMC: 11312717. DOI: 10.3390/jcm13154401.


Spectrum and Pattern of Movement Disorders in Patients with Sporadic Creutzfeldt-Jakob Disease.

Gurram S, Holla V, Sharma P, Kamble N, Saini J, Netravathi M Tremor Other Hyperkinet Mov (N Y). 2023; 13:14.

PMID: 37152622 PMC: 10162196. DOI: 10.5334/tohm.753.


Ataxias: Hereditary, Acquired, and Reversible Etiologies.

Lin C, Kuo S Semin Neurol. 2023; 43(1):48-64.

PMID: 36828010 PMC: 10354687. DOI: 10.1055/s-0043-1763511.


Genomic, transcriptomic and RNA editing analysis of human MM1 and VV2 sporadic Creutzfeldt-Jakob disease.

Tarozzi M, Baiardi S, Sala C, Bartoletti-Stella A, Parchi P, Capellari S Acta Neuropathol Commun. 2022; 10(1):181.

PMID: 36517866 PMC: 9749175. DOI: 10.1186/s40478-022-01483-9.

References
1.
Nihat A, Ranson J, Harris D, McNiven K, Mok T, Rudge P . Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob disease. Brain Commun. 2022; 4(4):fcac201. PMC: 9374480. DOI: 10.1093/braincomms/fcac201. View

2.
Edler J, Mollenhauer B, Heinemann U, Varges D, Werner C, Zerr I . Movement disturbances in the differential diagnosis of Creutzfeldt-Jakob disease. Mov Disord. 2008; 24(3):350-6. DOI: 10.1002/mds.22253. View

3.
Collinge J . Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001; 24:519-50. DOI: 10.1146/annurev.neuro.24.1.519. View

4.
Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O . Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999; 46(2):224-33. View

5.
Nihat A, Mok T, Odd H, Thompson A, Caine D, McNiven K . Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2022; 93(4):404-412. PMC: 8921594. DOI: 10.1136/jnnp-2021-327722. View